Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
1+ hour, 35+ min ago (758+ words) Sep 15, 2026, 12:20 ET BOSTON, Sept. 15, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced final fifteen-month results from its Phase 1/2 clinical trial evaluating SKY-0515, an investigational oral treatment for Huntington's…...
Definium Reports Second Phase III Success in Anxiety Disorder Program
3+ hour, 39+ min ago (353+ words) Year to date, Definium stock has skyrocketed 200.6% against the industry's 2.9% decline. Beyond GAD, Definium is advancing DT120 ODT in major depressive disorder (MDD). DFTX's phase III Emerge study delivered positive top-line results in June 2026, meeting its primary and key secondary endpoints. The…...
H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial
10+ hour, 23+ min ago (128+ words) TradingView H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial H. Lundbeck A/S said the last patient has been randomized in DEEp SEA, a global Phase III trial of bexicaserin for seizures in Dravet syndrome; over 100 participants enrolled,…...
A Single Dose of Pharmaceutical LSD Cut Anxiety Scores Five Points Below Placebo in Phase 3 Trial
18+ hour, 54+ min ago (773+ words) A single dose of a pharmaceutical formulation of LSD cut anxiety scores by about 5 points more than placebo over 12 weeks, according to topline results from the Panorama study released Monday by Definium Therapeutics. Panorama enrolled 245 adults with generalized anxiety disorder…...
Definium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study
11+ hour, 16+ min ago (321+ words) clinicaltrialvanguard.com Definium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study Definium Therapeutics reported positive topline data from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder on September 14, 2026, a result that matters because GAD pharmacotherapy has run on…...
VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options
22+ hour, 26+ min ago (81+ words) TradingView VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options The session highlighted progress in commercial and clinical programs for RAS/MAPK-driven therapies, including a strong launch for the CO-PACK in ovarian cancer…...
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
1+ day, 14+ hour ago (484+ words) Definium Therapeutics to Discuss Topline Results from Phase 3 Pan The National Law Review Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK--(BUSINESS WIRE)…...
Can Acetylcholine Receptor Antibody Profiling Predict FcRn Therapy Outcomes in MG?
4+ day, 16+ hour ago (296+ words) Dr. Iorio: My name is Raffaele Iorio. I’m an associate professor of neurology at the Universita Cattolica del Sacro Cuore in Rome, Italy. I am also a staff neurologist at the Fondazione Policlinico Gemelli in Rome, Italy. Rare Diseases Today:…...
ARWR: Strong efficacy, safety, and launch readiness position plozasiran for high-impact SHTG entry
5+ day, 1+ hour ago (83+ words) tradingview.com Recent clinical data for plozasiran in SHTG show strong efficacy and a differentiated safety profile, with positive physician feedback and a focus on high-risk patient segments. Launch preparations are advanced, pricing has been well received by payers, and…...
Biovie seeks FDA meeting to plan Phase 3 trial for Parkinson's drug
5+ day, 4+ hour ago (532+ words) Planned study of bezisterim would enroll 175 adults with early-stage disease Written by Andrea Lobo | Sept. 10, 2026 Bezisterim, an experimental oral small molecule that Biovie is developing for people with early-stage Parkinson’s disease, is moving toward Phase 3 clinical testing, with the company…...